A new BIOCENTURY analysis lays out how “similar regulatory clocks” can lead to divergent study start timelines, emphasizing operational variables beyond regulatory acceptance. The report argues that dedicated trial units, site operations, and review structure collectively shape how quickly trials progress to first patient. The framing matters for sponsors because it shifts the bottleneck from regulatory theory to execution mechanics: staffing readiness, site activation efficiency, and internal review pipelines that determine time-to-start. The piece also highlights that even with standardized regulatory milestones, sponsors can end up with different first-patient outcomes due to trial-unit design and operational readiness. For biotech teams managing global timelines, the update underscores that predictable study start depends on end-to-end process discipline rather than only regulatory strategy.